Bionano Genomics (BNGO) Change in Accured Expenses (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 190.37% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (up 74.42% YoY), and the FY2025 full-year result was -$580000.0, up 74.06% from the prior year.
• Change in Accured Expenses eased to -$1.4 million in Q1 2026, from $522000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.5 million in Q3 2022 to a low of -$5.3 million in Q2 2024.
• A 5-year average of -$375823.5 and a median of -$546000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses tumbled 1073.1% in 2022 and jumped 424.54% in 2024, its largest moves.
• Tracing BNGO's Change in Accured Expenses over 5 years: stood at -$1.7 million in 2022, then tumbled by 105.11% to -$3.5 million in 2023, then jumped by 84.35% to -$546000.0 in 2024, then surged by 195.6% to $522000.0 in 2025, then sank by 371.46% to -$1.4 million in 2026.
• Business Quant data shows BNGO's Change in Accured Expenses at -$1.4 million in Q1 2026, $522000.0 in Q4 2025, and $721000.0 in Q3 2025.